PLUS vs REGN
ePlus inc (PLUS) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
ePlus inc (PLUS) is a software - application company listed on NASDAQ.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported PLUS revenue for 2025-03-31 was $2.07B. Net income was $108.0M. Revenue was down 7.0% from 2024-03-31 to 2025-03-31. PLUS currently screens at market cap $2.10B and trailing P/E 17.1.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
PLUS currently screens at market cap $2.10B and trailing P/E 17.1. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the PLUS and REGN stock pages for the full models.
Not investment advice.